All-trans retinoic acid added to treatment of primary immune thrombocytopenia: a systematic review and meta-analysis

All-trans retinoic acid (ATRA) application is a novel treatment approach for primary immune thrombocytopenia (ITP). This study aimed to evaluate the efficacy and safety of ATRA in the treatment of ITP. The databases of PubMed (MEDLINE), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and China National Knowledge Internet were searched on August 5, 2022, to find randomized controlled trials (RCTs) and observational studies. Five observational studies and four RCTs from China were included, and 760 Chinese patients were analyzed. In the five observational studies, the pooled overall response rate (ORR) and complete response rate (CRR) were 59.5% (95% confidence interval [CI], 52.4–66.4%) and 20.6% (95% CI, 14.3–27.6%), respectively. In the selected four RCTs, the pooled odds ratios for sustained response rate, ORR, and CRR were 3.00 (95% CI, 1.97–4.57; P < 0.01), 3.21 (95% CI, 2.15–4.78; P < 0.01), and 2.12 (95% CI, 1.17–3.86; P = 0.01), respectively. ATRA was associated with a reduction in relapse rate and salvage treatment rate (odds ratio, 0.30; 95% CI, 0.18–0.50; P < 0.01; 0.36; 95% CI, 0.23–0.56; P < 0.01, respectively). The pooled odds ratios for grade 1–2 dry skin, headache (or dizziness), and rash acneiform were 49.99 (95% CI, 16.05–155.67; P < 0.01), 1.75 (95% CI, 0.98–3.12; P = 0.06), and 0.37 (95% CI, 0.10–1.34; P = 0.13), respectively. This study suggests that ATRA may significantly improve the initial and long-term response of patients with ITP.